+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pulmonary Drugs Market - Global Forecast 2026-2032- Product Image
Pulmonary Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Pulmonary Drugs Market - Global Forecast 2026-2032

  • Report

  • 188 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4829825
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Pulmonary Drugs Market is projected to reach USD 24.68 Billion in 2026. It is expected to continue growing at a CAGR of 8.48%, reaching USD 40.01 Billion by 2032.

The pulmonary drugs market is being reshaped by the global burden of chronic respiratory disease, infectious lung disease, and rare pulmonary vascular disorders. The World Health Organization identifies COPD as the third leading cause of death worldwide, with 3.23 million deaths in 2019, while asthma affected an estimated 262 million people and caused 455,000 deaths in the same year. These epidemiological realities keep demand high for inhaled bronchodilators, inhaled corticosteroids, combination inhalers, antibiotics, antifibrotics, biologics, and pulmonary arterial hypertension therapies.

Growth is increasingly tied to precision respiratory medicine. Treatment decisions are moving beyond symptom control toward phenotype-guided asthma biologics, eosinophil-informed COPD care, antifibrotic intervention in progressive fibrosing lung disease, and guideline-based pulmonary hypertension management. For manufacturers, payers, and healthcare systems, competitive advantage now depends on clinical differentiation, adherence support, real-world evidence, sustainable inhaler portfolios, and access strategies that address both high-income markets and underserved respiratory populations.

Transformative Shifts in the Pulmonary Drug Landscape

The pulmonary drugs landscape is shifting from broad maintenance therapy to targeted, outcomes-oriented care. GOLD and GINA recommendations have accelerated the use of dual bronchodilation, selective inhaled corticosteroid use, and biologics for severe asthma phenotypes, while the 2024 U.S. approval of ensifentrine for COPD introduced a first-in-class inhaled PDE3/PDE4 option. In pulmonary arterial hypertension, the 2024 FDA approval of sotatercept expanded the treatment paradigm beyond vasodilation toward disease-modifying pathway intervention.

The market is also being transformed by delivery innovation and environmental pressure. Metered-dose inhalers remain essential, but manufacturers are responding to carbon-reduction policies by developing lower-global-warming-potential propellants and expanding dry-powder or soft-mist formats where clinically appropriate. At the same time, digital inhalers, remote monitoring, and adherence analytics are turning pulmonary drugs into connected therapeutic ecosystems rather than stand-alone prescriptions.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical accelerator across pulmonary drug discovery, clinical development, and commercialization. AI-enabled screening can help identify druggable inflammatory, fibrotic, and vascular targets, while computational modeling supports formulation optimization for inhaled particles, lung deposition, and device performance. In clinical trials, AI is increasingly used to enrich patient selection through imaging, spirometry trends, biomarkers, and electronic health record data.

Regulatory oversight is evolving with adoption. The U.S. FDA has reported more than 300 drug and biologic submissions referencing AI or machine learning between 2016 and 2023, underscoring the need for transparent model validation and bias controls. For pulmonary drugs, the cumulative impact will be strongest where AI improves exacerbation prediction, adherence management, site selection, pharmacovigilance, and real-world evidence generation without replacing clinical judgment.

Key Regional Insights: Asia-Pacific, North America, Europe, and Emerging Regions

Asia-Pacific is central to long-term pulmonary drug demand because of large patient populations, urban air pollution exposure, tobacco use, and expanding healthcare access across China, India, Japan, South Korea, Australia, and ASEAN markets. China and India carry substantial respiratory disease burdens linked to air quality, biomass exposure, smoking, and underdiagnosis, while Japan, South Korea, and Australia support earlier adoption of biologics, pulmonary hypertension therapies, antifibrotics, and advanced inhalation platforms through mature reimbursement systems and specialist respiratory care.

North America remains a high-value pulmonary drugs market due to established guideline adoption, strong specialty care networks, FDA innovation pathways, and broad use of respiratory biologics, combination inhalers, and orphan pulmonary therapies. Europe benefits from coordinated clinical guidelines, mature pharmacovigilance, and health technology assessment discipline, while the European Union is increasingly influential in sustainable inhaler policy and low-carbon respiratory care. Latin America, led by Brazil and Mexico, shows rising demand for affordable inhaled therapies, stronger public-sector access, and biologics access programs for severe asthma and other high-need respiratory conditions. The Middle East, particularly GCC countries, is investing in specialty respiratory care, pulmonary hypertension programs, and hospital infrastructure, while Africa presents major access needs for asthma, COPD, tuberculosis-related lung disease, post-infectious respiratory impairment, and essential inhaled medicines.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are gaining importance as governments expand universal health coverage, respiratory diagnostics, and access to essential inhaled medicines, although affordability, distribution reliability, and correct inhaler technique remain decisive barriers. The GCC is characterized by high healthcare investment, specialty hospital capacity, and growing demand for asthma, COPD, and pulmonary hypertension treatments, supported by national healthcare modernization programs in Saudi Arabia, the UAE, Qatar, and neighboring states.

The European Union shapes the pulmonary drugs market through centralized regulation, pharmacovigilance standards, health technology assessment, cross-border evidence expectations, and climate-focused inhaler policy. BRICS countries represent scale, manufacturing capability, and access challenges, particularly in China, India, Brazil, Russia, and South Africa, where respiratory disease burdens intersect with pricing pressure and local production priorities. G7 markets drive premium innovation, biologic uptake, rare pulmonary disease treatment adoption, and real-world evidence standards, while NATO member countries overlap with many high-income respiratory markets where supply resilience, essential medicines security, and domestic manufacturing are increasingly strategic priorities.

Key Country Insights Across Major Pulmonary Drug Markets

The United States leads in pulmonary drug innovation, with strong uptake of asthma biologics, COPD combination inhalers, pulmonary arterial hypertension therapies, and new options such as ensifentrine and sotatercept. Canada emphasizes evidence-based reimbursement and provincial formulary evaluation, while Mexico and Brazil require access-sensitive pricing, public-sector distribution strategies, and reliable availability of inhaled maintenance therapies. In Europe, the United Kingdom, Germany, France, Italy, and Spain combine high respiratory disease awareness with health technology assessment scrutiny; Germany and France are particularly important for specialty drug reimbursement, early evidence review, and real-world evidence expectations.

Russia remains a complex respiratory market affected by localization, supply continuity, and formulary considerations. China is expanding domestic innovation, regulatory modernization, respiratory specialty capacity, and access to advanced asthma, COPD, and pulmonary hypertension treatments, while India combines high respiratory disease burden with large generic manufacturing strength and demand for affordable inhalers. Japan, South Korea, and Australia support advanced care models, biologics, antifibrotics, and pulmonary hypertension therapies through mature regulatory systems, specialist networks, and high clinical guideline adherence.

Actionable Recommendations for Pulmonary Drug Leaders

Industry vendors should prioritize differentiated clinical evidence that demonstrates fewer exacerbations, better lung function, improved quality of life, slower disease progression where relevant, and reduced healthcare utilization. Strong value dossiers are essential because payers increasingly compare inhaled combinations, biologics, antifibrotics, and pulmonary hypertension therapies against measurable outcomes, safety, adherence, and total cost of care.

Companies should also invest in device usability, adherence support, patient education, and sustainable inhaler transitions without compromising patient technique or therapeutic equivalence. Portfolio strategies should balance premium biologics and specialty therapies with affordable essential medicines for emerging markets. Partnerships with diagnostics providers, digital health platforms, respiratory centers, and public health stakeholders can strengthen phenotype identification, trial recruitment, post-launch evidence generation, and equitable access to pulmonary drugs.

Research Methodology

This executive summary is based on triangulation of public health data, regulatory information, clinical guideline trends, and industry-standard market assessment practices. Core evidence sources include WHO respiratory disease statistics, national regulatory announcements, peer-reviewed clinical literature, and guideline frameworks from organizations such as GOLD and GINA.

The analysis evaluates pulmonary drugs by therapeutic class, disease area, delivery format, regulatory momentum, regional access conditions, sustainability considerations, and competitive differentiation. Insights are validated through cross-comparison of epidemiology, approvals, reimbursement dynamics, clinical adoption patterns, and real-world implementation factors to ensure that conclusions remain evidence-led, commercially relevant, and free from unsupported market sizing or forecasting assumptions.

Conclusion

The pulmonary drugs market is entering a more precise, connected, and evidence-intensive era. COPD, asthma, pulmonary arterial hypertension, interstitial lung disease, and infectious respiratory conditions continue to create substantial clinical need, while biologics, first-in-class small molecules, antifibrotics, and optimized inhalation technologies expand the treatment toolkit.

Future market leadership will depend on more than product efficacy alone. Organizations that integrate biomarker-driven care, AI-supported development, sustainable devices, equitable access, and robust real-world evidence will be best positioned to compete in a global respiratory therapeutics landscape shaped by both innovation and affordability.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Pulmonary Drugs Market, by Product Type
7.1. Introduction
7.2. Biologics
7.2.1. Anti-IgE antibodies
7.2.2. Anti-IL-4/IL-13 inhibitors
7.2.3. Anti-IL-5 / IL-5R inhibitors
7.3. Bronchodilators
7.3.1. Beta-2 Agonists
7.3.2. Anticholinergics
7.3.3. Methylxanthines
7.4. Combination Therapies
7.5. Inhaled Corticosteroids
7.5.1. Beclomethasone
7.5.2. Budesonide
7.5.3. Fluticasone
8. Pulmonary Drugs Market, by Route Of Administration
8.1. Introduction
8.2. Inhalation
8.2.1. Dry Powder Inhalers
8.2.2. Metered Dose Inhalers
8.2.3. Nebulizers
8.3. Injection
8.3.1. Prefilled Syringes
8.3.2. Vials
8.4. Oral
8.4.1. Capsules
8.4.2. Liquids
8.4.3. Tablets
9. Pulmonary Drugs Market, by Age Group
9.1. Introduction
9.2. Pediatric
9.3. Adult
9.4. Geriatric
10. Pulmonary Drugs Market, by Indication
10.1. Introduction
10.2. Asthma
10.3. Chronic Obstructive Pulmonary Disease (COPD)
10.4. Cystic Fibrosis
10.5. Interstitial Lung Disease
10.6. Pulmonary Fibrosis
10.7. Pulmonary Hypertension
10.8. Respiratory Infections
11. Pulmonary Drugs Market, by End User
11.1. Introduction
11.2. Ambulatory Care Centers
11.3. Homecare Settings
11.4. Hospitals
11.5. Specialty Clinics
12. Pulmonary Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Offline Pharmacies
12.3. Online Pharmacies
13. Pulmonary Drugs Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East
14. Pulmonary Drugs Market, by Group
14.1. NATO
14.2. G7
14.3. BRICS
14.4. European Union
14.5. ASEAN
14.6. GCC
15. Pulmonary Drugs Market, by Country
15.1. China
15.2. United States
15.3. India
15.4. Japan
15.5. Germany
15.6. United Kingdom
15.7. Australia
15.8. South Korea
15.9. France
15.10. Canada
15.11. Italy
15.12. Brazil
15.13. Mexico
15.14. Russia
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. 4D Molecular Therapeutics, Inc.
17.2. AbbVie Inc.
17.3. Aer Therapeutics, Inc.
17.4. Aerogen Ltd.
17.5. Alembic Pharmaceuticals Limited
17.6. Amgen Inc.
17.7. AstraZeneca PLC
17.8. Avalyn Pharma Inc.
17.9. Bayer AG
17.10. Bespak Limited
17.11. Boehringer Ingelheim International GmbH
17.12. Bristol Myers Squibb Company
17.13. Chiesi Farmaceutici S.p.A.
17.14. Cipla Limited
17.15. Cumberland Pharmaceuticals Inc.
17.16. Dr. Reddy’s Laboratories Limited
17.17. F. Hoffmann-La Roche Ltd
17.18. GlaxoSmithKline plc
17.19. Glenmark Pharmaceuticals Limited
17.20. Insmed Incorporated
17.21. Lupin Limited
17.22. Merck & Co., Inc.
17.23. Novartis AG
17.24. Pfizer Inc.
17.25. Sanofi S.A.
17.26. Sun Pharmaceutical Industries Limited
17.27. Teva Pharmaceutical Industries Ltd.
17.28. Theravance Biopharma, Inc.
17.29. Vertex Pharmaceuticals Incorporated
17.30. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL PULMONARY DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL PULMONARY DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL PULMONARY DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL PULMONARY DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL PULMONARY DRUGS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
FIGURE 11. GLOBAL PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL PULMONARY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL PULMONARY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL PULMONARY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL PULMONARY DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL PULMONARY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL PULMONARY DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL ANTI-IGE ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL ANTI-IGE ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL ANTI-IGE ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL ANTI-IL-4/IL-13 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL ANTI-IL-4/IL-13 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL ANTI-IL-4/IL-13 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL ANTI-IL-5 / IL-5R INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL ANTI-IL-5 / IL-5R INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL ANTI-IL-5 / IL-5R INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL BRONCHODILATORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL BRONCHODILATORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL BETA-2 AGONISTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL BETA-2 AGONISTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL BETA-2 AGONISTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL ANTICHOLINERGICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL ANTICHOLINERGICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL ANTICHOLINERGICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL METHYLXANTHINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL METHYLXANTHINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL METHYLXANTHINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL INHALED CORTICOSTEROIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL INHALED CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL INHALED CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL BECLOMETHASONE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL BECLOMETHASONE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL BECLOMETHASONE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL BUDESONIDE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL BUDESONIDE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL BUDESONIDE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL FLUTICASONE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL FLUTICASONE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL FLUTICASONE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL INHALATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL INHALATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL INHALATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL DRY POWDER INHALERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL DRY POWDER INHALERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL DRY POWDER INHALERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL METERED DOSE INHALERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL METERED DOSE INHALERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL METERED DOSE INHALERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL NEBULIZERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL NEBULIZERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL NEBULIZERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL INJECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL INJECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL INJECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL PREFILLED SYRINGES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL PREFILLED SYRINGES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL PREFILLED SYRINGES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL VIALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL VIALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL VIALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL LIQUIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL LIQUIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL LIQUIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL TABLETS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL ASTHMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL ASTHMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL ASTHMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL INTERSTITIAL LUNG DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL INTERSTITIAL LUNG DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL INTERSTITIAL LUNG DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL PULMONARY FIBROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL PULMONARY FIBROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL PULMONARY HYPERTENSION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL PULMONARY HYPERTENSION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL PULMONARY HYPERTENSION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL RESPIRATORY INFECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL RESPIRATORY INFECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL RESPIRATORY INFECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL OFFLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL OFFLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL OFFLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2017-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 143. EUROPE PULMONARY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 144. EUROPE PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 145. EUROPE PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 146. EUROPE PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2017-2032 (USD MILLION)
TABLE 147. EUROPE PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 148. EUROPE PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 149. EUROPE PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 150. EUROPE PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 151. EUROPE PULMONARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 152. EUROPE PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 153. EUROPE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 154. EUROPE PULMONARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 155. EUROPE PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 156. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 157. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 158. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 159. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2017-2032 (USD MILLION)
TABLE 160. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 161. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 162. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 163. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 164. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 165. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 166. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 167. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 168. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 169. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 170. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 171. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 172. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2017-2032 (USD MILLION)
TABLE 173. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 174. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 175. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 176. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 177. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 178. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 179. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 180. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 181. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 182. AFRICA PULMONARY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 183. AFRICA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 184. AFRICA PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 185. AFRICA PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2017-2032 (USD MILLION)
TABLE 186. AFRICA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 187. AFRICA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 188. AFRICA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 189. AFRICA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 190. AFRICA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 191. AFRICA PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 192. AFRICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 193. AFRICA PULMONARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 194. AFRICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 195. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 196. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 197. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 198. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2017-2032 (USD MILLION)
TABLE 199. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 200. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 201. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 202. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 203. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 204. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 205. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 206. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 207. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 208. GLOBAL PULMONARY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 209. NATO PULMONARY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 210. NATO PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 211. NATO PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 212. NATO PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2017-2032 (USD MILLION)
TABLE 213. NATO PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 214. NATO PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 215. NATO PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 216. NATO PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 217. NATO PULMONARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 218. NATO PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 219. NATO PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 220. NATO PULMONARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 221. NATO PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 222. G7 PULMONARY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 223. G7 PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 224. G7 PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 225. G7 PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2017-2032 (USD MILLION)
TABLE 226. G7 PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 227. G7 PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 228. G7 PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 229. G7 PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 230. G7 PULMONARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 231. G7 PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 232. G7 PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 233. G7 PULMONARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 234. G7 PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 235. BRICS PULMONARY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 236. BRICS PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 237. BRICS PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 238. BRICS PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2017-2032 (USD MILLION)
TABLE 239. BRICS PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 240. BRICS PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 241. BRICS PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 242. BRICS PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 243. BRICS PULMONARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 244. BRICS PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 245. BRICS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 246. BRICS PULMONARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 247. BRICS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 248. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 249. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 250. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 251. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2017-2032 (USD MILLION)
TABLE 252. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 253. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 254. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 255. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 256. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 257. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 258. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 259. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 260. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 261. ASEAN PULMONARY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 262. ASEAN PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 263. ASEAN PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 264. ASEAN PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2017-2032 (USD MILLION)
TABLE 265. ASEAN PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 266. ASEAN PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 267. ASEAN PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 268. ASEAN PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 269. ASEAN PULMONARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 270. ASEAN PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 271. ASEAN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 272. ASEAN PULMONARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 273. ASEAN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 274. GCC PULMONARY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 275. GCC PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 276. GCC PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 277. GCC PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2017-2032 (USD MILLION)
TABLE 278. GCC PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 279. GCC PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 280. GCC PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 281. GCC PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 282. GCC PULMONARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 283. GCC PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 284. GCC PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 285. GCC PULMONARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 286. GCC PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 287. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 288. CHINA PULMONARY DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 289. CHINA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 290. CHINA PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 291. CHINA PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2017-2032 (USD MILLION)
TABLE 292. CHINA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 293. CHINA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 294. CHINA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 295. CHINA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 296. CHINA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 297. CHINA PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 298. CHINA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 299. CHINA PULMONARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 300. CHINA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 301. UNITED STATES PULMONARY DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 302. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 303. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 304. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2017-2032 (USD MILLION)
TABLE 305. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 306. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 307. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 308. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 309. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 310. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 311. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 312. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 313. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 314. INDIA PULMONARY DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 315. INDIA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 316. INDIA PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 317. INDIA PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2017-2032 (USD MILLION)
TABLE 318. INDIA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 319. INDIA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 320. INDIA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 321. INDIA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 322. INDIA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 323. INDIA PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 324. INDIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 325. INDIA PULMONARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 326. INDIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 327. JAPAN PULMONARY DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 328. JAPAN PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 329. JAPAN PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 330. JAPAN PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2017-2032 (USD MILLION)
TABLE 331. JAPAN PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 332. JAPAN PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 333. JAPAN PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 334. JAPAN PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 335. JAPAN PULMONARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 336. JAPAN PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 337. JAPAN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 338. JAPAN PULMONARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 339. JAPAN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 340. GERMANY PULMONARY DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 341. GERMANY PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 342. GERMANY PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 343. GERMANY PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2017-2032 (USD MILLION)
TABLE 344. GERMANY PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 345. GERMANY PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 346. GERMANY PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 347. GERMANY PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 348. GERMANY PULMONARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 349. GERMANY PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 350. GERMANY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 351. GERMANY PULMONARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 352. GERMANY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 353. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 354. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 355. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 356. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2017-2032 (USD MILLION)
TABLE 357. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 358. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 359. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 360. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 361. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 362. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 363. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 364. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 365. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 366. AUSTRALIA PULMONARY DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 367. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 368. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 369. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2017-2032 (USD MILLION)
TABLE 370. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 371. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 372. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 373. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 374. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 375. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 376. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 377. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY END USER, 201

Companies Mentioned

  • 4D Molecular Therapeutics, Inc.
  • AbbVie Inc.
  • Aer Therapeutics, Inc.
  • Aerogen Ltd.
  • Alembic Pharmaceuticals Limited
  • Amgen Inc.
  • AstraZeneca PLC
  • Avalyn Pharma Inc.
  • Bayer AG
  • Bespak Limited
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Chiesi Farmaceutici S.p.A.
  • Cipla Limited
  • Cumberland Pharmaceuticals Inc.
  • Dr. Reddy’s Laboratories Limited
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Limited
  • Insmed Incorporated
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Theravance Biopharma, Inc.
  • Vertex Pharmaceuticals Incorporated
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages188
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 24.68 Billion
Forecasted Market Value ( USD ) by 2032 $ 40.01 Billion
Compound Annual Growth Rate8.4%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

Pulmonary Drug Delivery Devices Market - Global Forecast 2026-2032 - Product Image

Pulmonary Drug Delivery Devices Market - Global Forecast 2026-2032

  • Report
  • 194 Pages
  • Global
From
Inhalation Pulmonary Drug Delivery Devices Market - Global Forecast 2026-2032 - Product Image

Inhalation Pulmonary Drug Delivery Devices Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Pulmonary Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Pulmonary Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 114 Pages
  • Global
From
Pulmonary Drugs Market Report 2026 - Product Image

Pulmonary Drugs Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Pulmonary Drug Delivery Systems - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Pulmonary Drug Delivery Systems - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 117 Pages
  • Global
From

About the Pulmonary Drug Market

The Pulmonary Drug market is a subset of the larger Respiratory Drug market, which includes treatments for a variety of respiratory diseases and conditions. Pulmonary Drugs are used to treat diseases and conditions of the lungs, such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and pulmonary hypertension. These drugs are typically inhaled, and can include bronchodilators, corticosteroids, and antibiotics. In addition, Pulmonary Drugs can also be used to treat other respiratory conditions, such as sleep apnea and snoring. The Pulmonary Drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include GlaxoSmithKline, Merck & Co., Novartis, Pfizer, and AstraZeneca. Other companies, such as Boehringer Ingelheim, Cipla, and Sun Pharmaceuticals, also offer Pulmonary Drugs. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.